Skip to main content

Moderna Therapeutics and Novamax Begin Human Trials for COVID-19

Moderna Therapeutics and Novamax Begin Human Trials for COVID-1. Development progress of coronavirus therapy in Wuhan

Let us understand the situation throughly from beginning to end. Patients with new coronavirus infections that originated in Wuhan, China in December 2019 have been discovered and confirmed in many countries and regions. The geographic extent of the virus's spread and its recently discovered ability to spread through human-to-human contact have caused health officials to worry about the possibility of global spread.

As health officials scramble to learn more about the virus and its origins, researchers are working hard to develop vaccines or therapies that can help curb the global spread of the virus. Experts believe that this is technically feasible, but it also faces challenges.

Dr. Ralph Baric, who studies coronavirus at the School of Global Public Health at the University of North Carolina at Gillins University, said that the Wuhan virus (officially named 2019-nCoV) belongs to the coronavirus family. This category includes SARS (Severe Acute) Respiratory Syndrome, Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome, Middle East Respiratory Syndrome).

Although the new coronavirus is not exactly the same as SARS, their similarity allows scientists to use previous research experience and results to accelerate the development of vaccines and drugs against Wuhan coronavirus.

Dr. Anthony Fauci, long-time director of the National Institute of Allergy and Infectious Diseases (NIAID), said that after the SARS outbreak in 2003, researchers produced a vaccine and pushed it forward.

The first phase of human trials to test the safety of new drugs, but this effort has never made further progress, mainly due to the shift of research focus of participating units as the epidemic ended.

Dr. Fauci said that, theoretically, Chinese researchers have sequenced the Wuhan coronavirus. It should be fairly easy to adjust the SARS vaccine model for the unique aspects of Wuhan coronavirus.

Another option is to modify existing monoclonal antibodies that help the immune system attack foreign bodies such as viruses.

"You don't want to be too optimistic, you will indeed encounter obstacles, but fundamentally and conceptually, it is not difficult to achieve this."

Dr. Fauci added that NIAID is working with Moderna, a biotechnology company in Massachusetts, to put an experimental vaccine into a clinical trial.

He estimates that this process will take about three months and cost millions of dollars.

This does not mean that people can actually be vaccinated very quickly, because the first phase of the trial is only the first step towards safe human use, usually after animal studies and before human studies of drug efficacy.

Trials begin for Drug Development for Coronavirus by Moderna and Novamax

Whether these projects will proceed further depends largely on the results of the first phase of the trial, the duration and severity of the outbreak. But Dr. Fauci believes that the investment and efforts in this area are totally worthwhile.

Dr. Timothy Sheahan, who studies coronaviruses with Dr. Baric at the University of North Carolina, said that the development of vaccines may last longer than the disease. But this does not mean that the development of the remedy is not worth it.

The Ebola virus is a good example. In 2014, when the Ebola outbreak occurred in West Africa, it was too late when the drugs or vaccines were developed. However, when Ebola virus appeared again in Congo in 2018, the drug / vaccine has been developed. This time, the crisis was promptly responded to and the public health was improved.

 

Biotech company Moderna is developing vaccines for Wuhan coronavirus

On January 21, 2020, Moderna, a US biotechnology company founded in 2010, said in a stock exchange report that the company is working with the US government health agency to develop a vaccine for the current Wuhan coronavirus.

Specifically, the company is collaborating with the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Vaccine Research Center (VRC) to develop potential vaccines.

Moderna CEO Stephane Bancel revealed that they had produced a cancer vaccine within 40 days.

Tthey are now using the same technology for rapid development. In a document submitted to the US Securities and Exchange Commission, the company stated:

"As a fast and flexible platform, Moderna's mRNA vaccine technology is expected to be useful against emerging virus threats such as new coronaviruses.

Although we have not tested this before Rapid response capability, but Moderna confirms that it is working with NIH / NIAID / VRC to study potential vaccines for current public health emergencies. "


Development progress of coronavirus therapy in Wuhan

According to Amazon Web Services, Moderna is currently using Amazon's cloud platform to study more than a dozen drug candidates, seven of which are in human trials.

Cloud services are used to help accelerate the process from research to clinical trials.

Development progress of coronavirus therapy in Wuhan. Moderna, Novavax of the United States fully develop Wuhan coronavirus vaccine.

(Source: Moderna's official website)


The company stated that they have extensive history and extensive experience in coronavirus research including MERS and SARS and in the development of candidate vaccines.

The company said in a statement: "The company hopes to use Novavax's recombinant nanoparticle vaccine technology to develop a candidate vaccine based on the gene sequence of Wuhan coronavirus."

Novavax also plans to make full use of its proprietary Matrix-M adjuvant technology to strive to further enhance the immune response.

 

The Age of Medicine

In December 2019, patients with new coronavirus infections who had split their heads in Wuhan, China, have been found and confirmed in many countries and regions. The geographic reach of the virus and its recently discovered ability to spread through human-to-human contact have caused health officials to worry about the possibility of global spread.

As health officials scramble to learn more about the virus and its heads, researchers are working hard to develop vaccines or therapies that can help stop the virus from spreading globally. Experts believe that this is technically feasible, but it also faces provocation.

 

Dr. Ralph Baric, who studies coronavirus at the School of Global Public Health at the University of North Carolina at Gillins University, first described that the Wuhan virus (officially named 2019-nCoV) belongs to the coronavirus family.

This category includes SARS (Severe Acute Respiratory Syndrome, severe acute respiratory syndrome) and MERS (Middle East Respiratory Syndrome, Middle East Respiratory Syndrome).

Although the new coronavirus is not completely similar to SARS, but their similarity can enable scientists to use the previous research history and results to accelerate the development of vaccines and drugs against Wuhan coronavirus.

 

Dr. Anthony Fauci, who has long served as the director of the National Institute of Allergy and Infectious Diseases (NIAID), said that after the outbreak of SARS in 2003, researchers produced a vaccine and pushed it forward.

To the first phase of human trials to test the safety of new drugs, but this effort never achieved further hope, this is mainly due to the end of the epidemic on-site units shifted the focus of research.

 

According to Dr. Fauci, in theory, Chinese researchers have sequenced the Wuhan coronavirus, and it should be fairly easy to mediate the SARS vaccine model for the unique aspects of Wuhan coronavirus.

Another option is to modify existing monoclonal antibodies that help the immune system attack foreign bodies such as viruses. "You don't want to be overly optimistic, you will indeed encounter obstacles, but fundamentally and conceptually, it is not difficult to do this."

 

Dr. Fauci added that NIAID is working with Moderna, a biotechnology company in Massachusetts, to put an experimental vaccine into a phase 1 clinical trial. He estimates that this process will take about three months and cost millions of dollars.

This does not mean that people can actually be vaccinated very quickly, because the first phase of the trial is only the first step towards safe human use, usually after animal studies and before human studies of drug efficacy.

Whether these projects are further promoted depends largely on the effectiveness of the first phase of the trial, the duration and severity of the epidemic. But Dr. Fauci believes that the investment and efforts in this area are totally worth it.

 

Dr. Timothy Sheahan, who studied coronaviruses with Dr. Baric at the University of North Carolina, showed that the development of vaccines may last longer than the disease. But this does not mean that it is not worth opening up.

The Ebola virus is a good example. In 2014, when the Ebola outbreak occurred in West Africa, it was too late when the drugs or vaccines were developed.

However, when the Ebola virus appeared again in Congo in 2018, the development of drugs / vaccines was completed. This time, the crisis was promptly addressed and public health improved.

 

Biotech company Moderna Therapeutics is developing vaccines for Wuhan coronavirus

On January 21, 2020, Moderna, a US biotechnology company founded in 2010, reflected in a stock exchange report that the company is cooperating with the U.S. authorities' sanitary gas structure to develop a vaccine for the current Wuhan coronavirus.

Specifically, the company is working with the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Vaccine Research Center (VRC) to develop potential vaccines.

 

Stephane Bancel, chief executive officer of Moderna, revealed that they had produced a cancer vaccine within 40 days; they are now using similar technologies for rapid development. In a document submitted to the US Securities and Exchange Commission, the company said:

"As a platform for rapid mobility, Moderna's mRNA vaccine technology is expected to be effective against emerging virus threats (such as the new coronavirus).


Moderna confirms that it is working with NIH / NIAID / VRC

Although we have not tested this before Rapid response capability, but Moderna confirms that it is working with NIH / NIAID / VRC to study potential vaccines for current public health emergencies. "


According to Amazon Web Services, Moderna is now using Amazon's cloud platform to study more than a dozen drug candidates, seven of which are in human trials. Cloud services are used to help accelerate the process from research to clinical trials.

 

In the book of war on January 21, 2020, Novavax (NASDAQ: NVAX) of the United States showed that the company has started to develop candidate vaccines against Wuhan coronavirus.


Novavax's recombinant nanoparticle vaccine technology Use

According to the company, they have extensive history and rich experience in coronavirus research including MERS and SARS and the development of candidate vaccines. The company said in a statement:

"The company hopes to use Novavax's recombinant nano-particle vaccine technology to develop a candidate vaccine based on the gene sequence of Wuhan coronavirus."

 

Novavax is also planning to make full use of its proprietary Matrix-M adjuvant technology to capture and further enhance the immune response.


 

Comments

Popular posts from this blog

Vaginitis Treatment and Prevention

Prevention and Treatment of Vaginitis Q. I am 22 years old and just had sex this month. This time after finishing my aunt's itching, there are a lot of secretions. Did I have vaginitis? Super scared, what should I do? What should I do if my female ticket got vaginitis? OR     I have fungal vaginitis. It has not been good to reuse the medicine for 2 months. It is really shameful. I dare not let my roommate find that there is no way to go to the hospital every day.     The vagina was very itchy after coming to the aunt this time. I am now physically and mentally broken. I was nineteen and still in college. I'm not that kind of casual girl. I dare not talk to my family about such things. Too scared.    Ans. Vaginitis Study For obstetrics and gynecology, vaginitis is really the disease we are most familiar with. More than 50% of obstetrics and gynecology clinics are due to vaginitis. There are also people who originally checked for other diseases. As a result, a l

Loose or Relaxed Vagina Tightening

Relaxation of Vagina What should I do if my child's vagina relaxes after birth? Know that every woman enjoys the process of being a mother, because being a mother is very happy, even if you have a baby, you have a complete family. Sometimes, although happy, sometimes it is not sexually blessed, because the birth of a child will lead to vaginal relaxation, and vaginal relaxation will affect the quality of sexual life. So, what should be done after the child is born? Procedures to improve vaginal relaxation Traditional methods to improve vaginal relaxation at different levels: So, how should postpartum women, or women who have already experienced vaginal relaxation, do pelvic muscle training? The traditional Chinese health-care method of "collecting anus and lifting gas" can be well forged practice pelvic muscles.   Natural Method to Tighten Vagina Every morning and evening in a fresh air place, inhale deeply after inhaling. At the same time, like anxiety

How to Prepare for Electrocardiogram ECG Test?

Considerations Before Going for Electrocardiogram, ECG Test 1. Female examiners avoid wearing dresses 2. Avoid the influence of drugs  Some drugs directly or indirectly affect the results of electrocardiogram, such as digitalis, quinisil, etc.  This is because drugs affect the metabolism of the myocardium, people taking such drugs affect the ECG graphics. Therefore, you should explain to the doctor which medicines you have taken recently to avoid misdiagnosis. During ECG inspection: 1. Please relax as much as possible during the inspection to ensure the quality of the inspection. 2. Perform when the test is quiet. Bioelectricity is generated due to muscle activity. Crying, taking deep breaths and moving the limbs will affect the ECG results.  Thus, it should be done when the child or person is quiet.  If necessary, give the sick child some sedatives to prevent interference caused by other muscle activities. Interpretation of ECG ( Electrocardiog